Never miss a story

Get subscribed to our newsletter


×
Cancer Ribbon. Pixabay

MIT researchers, including one of Indian-origin, have developed novel machine-learning techniques to improve the quality of life for patients by reducing toxic chemotherapy and radiotherapy dosing for an aggressive form of brain cancer.

Glioblastoma is a malignant tumour that appears in the brain or spinal cord, and the prognosis for adults is no more than five years.


Patients are generally administered maximum safe drug doses to shrink the tumour as much as possible, but they still remain at risk of debilitating side effects.

The new “self-learning” machine-learning technique could make the dosing regimen less toxic but still effective.

It looks at the treatment regimen currently in use, and finds an optimal treatment plan, with the lowest possible potency and frequency of doses that should still reduce tumour sizes to a degree comparable to that of traditional regimen, the researchers said.

“We kept the goal where we have to help patients by reducing tumour sizes but, at the same time, we want to make sure the quality of life — the dosing toxicity — doesn’t lead to overwhelming sickness and harmful side effects,” said Pratik Shah, principal investigator from the Massachusetts Institute of Technology (MIT) in Boston, US.


Representational image. Pixabay

The findings will be presented at the 2018 Machine Learning for Healthcare conference at Stanford University in California, US.

In simulated trials of 50 patients, the model comprising of artificially intelligent “agents”, designed treatment cycles that reduced the potency to a quarter or half of nearly all the doses while maintaining the same tumour-shrinking potential.

Many times, it skipped doses altogether, scheduling administrations only twice a year instead of monthly.

You May Also Like to Read About The Relation of Cancer Cells With Immune System- Decoded: How Cancer Cells Cripple Immune System

However, the researchers also had to make sure the model does not just dish out a maximum number and potency of doses. Whenever the model chooses to administer all full doses, it gets penalized, so instead it chooses fewer, smaller doses.

“If all we want to do is reduce the mean tumour diameter, and let it take whatever actions it wants, it will administer drugs irresponsibly,” Shah said.

“Instead, we need to reduce the harmful actions it takes to get to that outcome.” (IANS)


Popular

Kishu Inu and Dogelon Mars are some of the more popular canine coins in recent months. Their popularity is demonstrated by the vast amount of trading volume that these cryptocurrencies receive.

At the time of writing, Kishu Inu has a trading volume exceeding $10 million and Dogelon Mars has an even larger trading volume that surpasses $30 million.

Keep Reading Show less

HUH Token

It’s here, and it appears that there ain’t nothin’ or no one stopping the skyrocketing force of HUH Token and the release of the long-awaited White Paper is finally here and we’re living for it.

It’s also great to note that Shiba Inu made a triumphant crypto market return this week and the reign of the dog continues though with HUH Token’s White Paper release it could see the ‘Utimeme’ token break out of the atmosphere on its December 6th launch and surpass Shiba Inu for altcoin supremacy.

Keep Reading Show less

HUH Token

HUH Token has been on the lips of crypto lovers for some time now and the much-anticipated White Paper release is here, right now, today!

Not only this but Shiba Inu’s mastery of the altcoin world could be coming to an end on HUH Token’s December 6th release if the aims, goals and technology in the White Paper are anything to go by.

Keep reading... Show less